NCT02895815 is a Phase 2 clinical trial of CNTO 2476 (6.0 * 10^4 cells) in Visual Acuity, sponsored by Janssen Pharmaceutical K.K..

Who is sponsoring NCT02895815?

NCT02895815 is sponsored by Janssen Pharmaceutical K.K..

What drugs are being tested in NCT02895815?

Interventions in NCT02895815: CNTO 2476 (6.0 * 10^4 cells), CNTO 2476 (3.0 * 10^5 cells).

What condition does NCT02895815 study?

NCT02895815 studies Visual Acuity, Geographic Atrophy, Macular Degeneration.

Is NCT02895815 still recruiting?

NCT02895815 is currently withdrawn. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT02895815

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Withdrawn Phase 2 Last updated 3 February 2025

What this trial tests

Phase 2 trial testing CNTO 2476 (6.0 * 10^4 cells) in Visual Acuity. Withdrawn.

Timeline

9 April 2018

Primary endpoint
20 February 2021

19 August 2022

Quick facts

Lead sponsor	Janssen Pharmaceutical K.K.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	9 April 2018
Primary completion	20 February 2021
Estimated completion	19 August 2022

Drugs / interventions tested

CNTO 2476 (6.0 * 10^4 cells)
CNTO 2476 (3.0 * 10^5 cells)

Conditions studied

Visual Acuity — all drugs for Visual Acuity →
Geographic Atrophy — all drugs for Geographic Atrophy →
Macular Degeneration — all drugs for Macular Degeneration →

Sponsor

Janssen Pharmaceutical K.K. — full company profile →

Who can join

Adults 50 to 90, any sex, with Visual Acuity or Geographic Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Retinal stem cell transplantation: Balancing safety and potential.
Singh MS, Park SS, Albini TA, Canto-Soler MV, et al · · 2020 · cited 177× · PMID 31494256 · DOI 10.1016/j.preteyeres.2019.100779
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease.
Martinez Velazquez LA, Ballios BG. · · 2021 · cited 18× · PMID 34768969 · DOI 10.3390/ijms222111542
Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.
Rojekar S, Parit S, Gholap AD, Manchare A, et al · · 2024 · cited 13× · PMID 39598522 · DOI 10.3390/pharmaceutics16111398

Verify or expand the search:

Other recruiting trials for Visual Acuity

Currently open trials in the same condition.

NCT07443215 — Evaluation of Effect of Scatter on Visual Performance · NA · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT07135180 — Exploring the Eye Care Benefits of Cordyceps Cicadae Across Different Age Groups · NA · active not recruiting
NCT04632901 — A New Parameter for the Assessment of Distance Visual Capacity: the Critical Visual Acuity (CVA) · active not recruiting

Other Janssen Pharmaceutical K.K. trials

Trials by the same sponsor.

NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa · Phase 3 · active not recruiting
NCT05567185 — A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer · Phase 1 · active not recruiting
NCT05167825 — A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension · Phase 3 · completed
NCT05242432 — A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02895815 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutical K.K.
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02895815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing